Propranolol interaction site

Herbette et al. compared the sorption site of the structurally similar tertiary amines propranolol and timolol [164]. Propranolol has a naphthalene substituent on the aliphatic chain, which is deeply incorporated into the hydrophobic core of the membrane. In contrast, timolol carries a partially charged morphine ring at the same place. This substituent, due to its polarity and partial charge, does not interact favourably with the membrane interior. Consequently, the AnW at pH 7.5 is 20 times higher for propranolol than for timolol, and timolol has less influence on the phase transition. 

More recently, Priego-Capote et al. reported on the production of MIP nanoparticles with monoclonal behaviour by miniemulsion polymerisation [63]. In the synthetic method that they employed, they devised to use a polymerisable surfactant that was also able to act as a functional monomer by interacting with the template (Fig. 4). The crosslinker content was optimised at 81% mol/mol (higher or lower contents leading to unstable emulsions). In this way, the authors were able not only to produce rather small particles (80-120 nm in the dry state) but also to locate the imprinted sites on the outer particle surface. The resulting MIP nanobeads were very effective as pseudostationary phases in the analysis of (/ ,S)-propranolol by CEC. 

Those agents that interact with calcium channels but have another primary site of action include agents acting on sodium channels (local anesthetics and phenytoin), catecholamine receptors (benextramine, nicergoline, phenoxy-benzamine, phenothiazines, pimozide, propranolol, and yohimbine derivatives), benzodiazepine receptors (diazepam and flurazepam), opiate receptors (loperamide and flu-peramide), and cyclic nucleotide phosphodiesterases (amrinone, cromoglycate, and papaverine), as well as barbiturates, cyproheptadine, indomethacin, and reserpine. 

Pharmacodynamic interactions are those where the effects of one drug are changed by the presence of another drug at its site of action. Sometimes the drugs directly compete for particular receptors (e.g. beta2 agonists, such as salbutamol, and beta blockers, such as propranolol) but often the reaction is more indirect and involves interference with physiological mechanisms. These interactions are much less easy to classify neatly than those of a pharmacokinetic type. 

For a good MIP, the monomer-ligand interactions are strong such that the good sites, arising from TM complexes, constitute a significant proportion of the total sites present. In such a case, the MIA solvent can be optimized such that a relatively small amount of MIP is used and yet the situation described as ideal in Fig. 8 still pertains. For instance, the S-propranolol MIA optimized by Andersson, the aqueous solvent was optimized such that only 50 pg of polymer was required per assay [38]. 

---